Amoéba lists on Euronext Paris

Raises €13.2 million, market capitalisation €44.5 million

Paris – 10 July 2015– EnterNext, the Euronext subsidiary dedicated to promoting and growing the market for small and medium-sized companies (SMEs),today celebrated the listing of Amoeba, a company producing a green biocide that eliminates bacterial risk in water. Amoeba is listed on the regulated market of Euronext Paris (Compartment C).

Based outside Lyon, France, in Chassieu, Amoeba produces an entirely natural biocide that eliminates risk from bacteria present in water—Legionella, Pseudomonas, Listeria and more. This biocide is an effective alternative to chemical biocide used to treat industrial water being returned to the environment. Its patented technology relies on unique expertise that uses an industrial production process based on a continuous suspension. Efficiency has been demonstrated successfully in tests at industrial sites and several businesses already use Amoeba’s biocide on an experimental basis. 

Amoeba (ticker code: AMEBA) was listed through the admission to trading on 10 July 2015 of the 5,358,157 ordinaryshares making up its equity, including 1,592,307 new shares issued through a Global Offering[1].

The admission and issue price of Amoeba shares was set at €8.30 per share. Market capitalisation was around €44.5 million on the day of listing, and the total amount raised was €13.2 million.

Fabrice Plasson, Preside of Amoeba’s Executive Board said: “We are delighted with the success of our listing, despite turmoil linked to events in Greece. And we would like to extend warm thanks to all of the new shareholders—both individuals and professionals—that have joined us today, as well as historic shareholders who also took part. Thanks, too, to the entire dynamic team at Amoeba that has rallied around with such enthusiasm. The funds raised will allow us to deploy our growth strategy for production and sales in target markets in Europe and North America.”

Eric Forest, CEO of EnterNext said: “We congratulate Amoeba on its successful market debut—proof that French and international investors are definitely on board for initiatives backed by strong equity stories, regardless of the macro-economic environment. Listing on Euronext has allowed Amoeba to raise the funds it needs to deploy a bold strategy aimed at revolutionising water treatment. As both an innovative business and an eco-business, Amoeba will be able to take full advantage of the tech industry initiatives rolled out by EnterNext.”



[1]The Global Offering was made up of a Public Offering that included an Open Price Public Offering and a Global Placement with institutional investors in France and other countries.

 

About EuronextEuronext is the leading pan-European exchange in the Eurozone, covering Belgium, France, Ireland, The Netherlands, Portugal and the UK. With 1,300 listed issuers worth €3.5 trillion in market capitalisation as of end March 2019, Euronext is an unmatched blue chip franchise that has 24 issuers in the Morningstar® Eurozone 50 Index℠ and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities ,FX,  Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, Euronext also operates Euronext GrowthTM and Euronext AccessTM, simplifying access to listing for SMEs.

Disclaimer
This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at www.euronext.com/terms-use.

© 2019, Euronext N.V. - All rights reserved.